MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21873/invivo.11129

Медицинская библиотека · In vivo (Athens, Greece) · 2017

Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma.

Kobari Yuki, Kondo Tsunenori, Takagi Toshio, Omae Kenji, Nakazawa Hayakazu, Tanabe Kazunari

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND/AIM: Rapid progressive disease (RPD), accelerated tumour growth immediate after the initiation of immune checkpoint inhibitor therapy, has been reported in melanoma and lung cancer. Herein, we describe 3 cases of RPD during the initial phase of nivolumab treatment for metastatic renal cell carcinoma.

PATIENTS AND

METHODS

The first and second patients received nivolumab in the fourth-line setting. The third patient received nivolumab therapy as third-line treatment.

RESULTS

The first patient developed severe respiratory failure due to carcinomatous lymphangiosis 14 days after initiation of nivolumab therapy. The second patient developed leg paraplegia due to rapid growth of the metastatic tumour at the sixth thoracic vertebrae 5 days later. The third patient developed grade 4 hypercalcemia due to RPD on day 3.

CONCLUSION

Clinicians should be aware of RPD during the initial phase of nivolumab therapy, especially in patients with critical lesions in the late-line setting.

Для цитирования: Kobari Yuki, Kondo Tsunenori, Takagi Toshio, Omae Kenji, Nakazawa Hayakazu, Tanabe Kazunari. Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma.. In vivo (Athens, Greece). 2017. DOI: 10.21873/invivo.11129.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.